+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • PDF Icon


  • 52 Pages
  • November 2018
  • Region: Global
  • GlobalData
  • ID: 4720463
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)


"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -
  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain

  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)

  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time

The report comprises three sections -

Executive Summary
  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.

Landscape Updates
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.

  • Timeline forecasts for each approved product’s lifecycle management initiatives.

  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline therapies.

Pipeline Landscape
  • An overview of pipeline candidates, containing snapshots of current development status.

  • Expected drug-specific events & milestones until YE 2020.

  • Current early stage RA pipeline & candidate ‘Watch List’.

  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)

  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix

  • Forecasts are presented in pipeline forecast figures & detailed tables

  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher

  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market

  • Reviews ongoing lifecycle management strategies for existing players in the market

  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Table of Contents

Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Afimmune

  • Akarna Therapeutics

  • Akero Therapeutics

  • Albireo

  • Allergan

  • Allergan (acquired from

  • Ardelyx

  • Arisaph

  • AstraZeneca

  • BHV Pharma Inc

  • Bird Rock Bio/Janssen

  • BMS

  • Boehringer Ingelheim

  • Can-Fite BioPharma

  • Celgene

  • Cempra

  • Cerenis Therapeutics

  • ChemomAb

  • Cirius Therapeutics

  • CohBar

  • ConSynance Therapeutics

  • CymaBay Therapeutics

  • DeuteRx

  • Dr. Falk Pharma GmbH

  • DURECT Corporation

  • Eli Lilly

  • Enanta

  • Galectin Therapeutics

  • Galmed

  • Gemcabene

  • Genfit

  • Gilead

  • GRI Bio

  • HighTide Biopharma

  • Immune Pharmaceuticals Inc.

  • Immuron

  • Intercept

  • INVENT Pharmaceuticals

  • Inventiva

  • Ionis Pharma-ceuticals

  • Janssen

  • Madrigal

  • MediciNova

  • Metacrine

  • Mitsubishi Tanabe

  • Naia

  • NGM Biopharmaceuticals

  • Nitto Denko

  • NorthSea Therapeutics

  • Novartis

  • Novo Nordisk

  • NuSirt BioPharma

  • Oramed

  • Pfizer

  • Poxel

  • Sanofi

  • Second Genome

  • Shire

  • Sinew Pharma

  • Sucampo Pharmaceuticals

  • Synairgen

  • Taiwan Pharmaceuticals

  • Teva

  • Tiziana Life Sciences

  • Valbiotis

  • Viking Therapeutics

  • Virobay

  • Zafgen

  • Zydus Discovery